immutep could be massive. Their lead scientist discovered LAG3. Their clinical programs in metastatic breast and head and neck cancer aren't that behind BMS with BMS data is in the crowded melanoma space. if LAG3 becomes the third space in check point Immunotherapies there could be a massive inflection in IMM SP. The leading global checkpoint inhibitor is Merck's Keytruda grew sales 30% to $14.4 billion USD annually in its last update, so any drug combination that keeps those type blockbuster programs relevant is incredibly valuable.
immutep could be massive. Their lead scientist discovered LAG3....
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $1.317M | 3.935M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73996 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 836970 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |